This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sami, M. Articles by DeBusk, R. F. Search for Related Content PubMed PubMed Citation Articles by Sami, M. Articles by DeBusk, R. F.

Circulation, Vol 62, 1172-1179, Copyright © 1980 by American Heart Association

ARTICLES

A new method for evaluating antiarrhythmic drug efficacy

M Sami, H Kraemer, DC Harrison, N Houston, C Shimasaki and RF DeBusk

To develop standards for distinguishing antiarrhythmic drug effect from spontaneous variability of premature ventricular complexes (PVCs), 21 males (mean age 56 +/- 8 years) with chronic ischemic heart disease and PVCs underwent symptom-limited treadmill exercise testing and 24-hour ambulatory monitoring before and after 2 weeks of placebo medication. Linear regression analysis was used to describe the relationship between baseline and placebo PVC frequency for various indexes of ventricular ectopic activity and to establish 95% and 99% one-tailed confidence intervals for this relationship within the group of 21 patients. The lower limit of baseline PVC frequency for which the procedure could distinguish a placebo from a true drug response, termed the "sensitivity threshold," was an average frequency of 2.2 PVCs/hour for ambulatory electrocardiographic monitoring and 1.2 PVCs/min for treadmill exercise testing. All patients exceeded the sensitivity threshold on baseline ambulatory ECGs, but only 38% of patients did so on baseline treadmill exercise tests. To establish antiarrhythmic efficacy with 95% confidence, the minimal percent reduction of PVCs between baseline and placebo visits was 68% for treadmill exercise testing and 65% for ambulatory electrocardiography. Although these standards were developed in patients with chronic ischemic heart disease, the model can be used to establish antiarrhythmic drug efficacy in any patient group.

This article has been cited by other articles:

				W. Britt Canada, W. Woodward, G. Lee, A. DeMaria, R. Low, D. T. Mason, A. Laddu, and W. Shapiro Circadian Rhythm of Hourly Ventricular Arrhythmia Frequency in Man Angiology, January 1, 1983; 34(4): 274 - 282. [PDF]